← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis. (2025/12/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD. (2025/12/05) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Primary bone marrow diffuse large B-cell lymphoma with secondary myelofibrosis: A case report. (2025/12/05) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report. (2025/12/05) ♡
• Non-invasive detection of bone marrow fibrosis in myeloproliferative neoplasms using cell-free RNA. (2025/12/03) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis. (2025/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. SH2B3 (Lnk) Mutations in Myeloid Neoplasms: Morphologic Spectrum, Co-Mutation Patterns, and Clinical Correlates. (2025/12/01) ♡
• Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib. (2025/12/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Glomerular Complications in Primary Myelofibrosis and the Role of Renal Transplantation: Systematic Review of The Current Evidence. (2025/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes? (2025/12/01) ♡
• Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study. (2025/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. TMEM91::TAL1 Fusion gene in a middle-aged female with rapid MDS to secondary AML progression: a case report. (2025/12/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes. (2025/12/01) ♡
• Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression. (2025/12/01) ♡
• Fedratinib in chronic kidney disease: antifibrotic potential and renal safety signals from integrated network toxicology and pharmacovigilance. (2025/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review]. (2025/12/01) ♡
• Gupta V, Tomuleasa C, Barranco Lampón GI, et al. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025;9(5):1105-1116. (2025/11/25) ♡
• European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis. (2025/11/24) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis. (2025/11/24) ♡
• Machine learning identifies inflammation-related diagnostic biomarkers for primary myelofibrosis with clinical validation. (2025/11/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A case report focusing on diagnosis and intervention of chronic myeloid leukemia in blast crisis (acute megakaryoblastic leukemia subtype). (2025/11/18) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model. (2025/11/15) ♡
• Prognostic utility of macrophage polarization (CD68/CD163 ratio) in Egyptian JAK2 positive myeloproliferative neoplasm patients: a single center study. (2025/11/14) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies. (2025/11/12) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Sweet's syndrome with Koebner phenomenon triggered by G-CSF as a preleukemic manifestation in a patient with primary myelofibrosis: a case report. (2025/11/10) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Masking as Myelofibrosis: A Case of Tp53 Mutated Acute Erythroid Leukemia Presenting With Pancytopenia and Bone Pain. (2025/11/04) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study. (2025/11/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Severe tophaceous gout in the setting of myelofibrosis: A clinical challenge. (2025/10/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics. (2025/10/29) ♡
• Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Other Myeloid Malignancies. (2025/10/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Advances in polycythemia vera treatment with targeted therapies and clinical trials. (2025/10/27) ♡
• A Case of Myeloproliferative Neoplasm-Associated Glomerulopathy in a Patient With Myelofibrosis. (2025/10/27) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Synergistic effects of deleting the tyrosine phosphatases Shp1 and Shp2 on megakaryopoiesis and thrombopoiesis in mice. (2025/10/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms. (2025/10/25) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Novel BMP2K::PDGFRA fusion in an unusual myeloid/lymphoid neoplasm with eosinophilia. (2025/10/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Spectrum of Kidney Biopsy Findings in a Patient With Primary Myelofibrosis. (2025/10/24) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms. (2025/10/23) ♡
• Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey. (2025/10/21) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis. (2025/10/21) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review. (2025/10/18) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: a case report. (2025/10/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Successful Neutrophil Engraftment with Continued Ruxolitinib in Cord Blood Transplantation. (2025/10/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Late Hypersensitivity Reaction to Hydroxyurea in a Patient With Myeloproliferative Disorder. (2025/10/16) ♡
• Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia vera. (2025/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Thoracoscopic Wedge Resection of Pulmonary Carcinoma with Myelofibrosis while Managing Thrombocytopenia: Report of a Case]. (2025/10/01) ♡
• Prevalence of Arterial Stiffness Determined by Cardio-Ankle Vascular Index in Myeloproliferative Neoplasms. (2025/09/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs). (2025/09/27) ♡
• Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib. (2025/09/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Airway Necrosis and Fungal Plaque Causing Central Airway Obstruction Due to Candida auris: A Case Report. (2025/09/23) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Genetic deletion of P-selectin prevents fibrosis development by inhibiting the neutrophil megakaryocyte emperipolesis in the Gata1(low) mouse model for myelofibrosis. (2025/09/22) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.